Adherence to pegylated combination therapy in patients with chronic hepatitis C.: Importance of the trio hepatologist, general practitioner, nurse

被引:5
|
作者
Wartelle-Bladou, C. [1 ,2 ]
Rosenthal, E. [3 ]
Ratziu, V. [4 ]
De Ledinghen, V. [5 ]
Lang, J. -P. [6 ]
Poynard, T. [4 ]
机构
[1] Ctr Hosp Pays Aix, Serv Hepatogastroenterol, F-13616 Aix En Provence 1, France
[2] Reseau Sante Prov, F-13770 Venelles, France
[3] Hop Archet 1, Serv Med Interne, F-06202 Nice 3, France
[4] Hop La Pitie Salpetriere, Serv Hepatogastroenterol, F-75013 Paris, France
[5] Hop Haut Leveque, Serv Hepatogastroenterol, F-33600 Pessac, France
[6] Ctr Hosp Erstein, F-67152 Erstein, France
来源
关键词
hepatitis C; compliance; general practitioner; ribavirin; peginterferon alpha-2b; peginterferon alpha-2a;
D O I
10.1016/S0399-8320(08)73272-X
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Adhesion to pegylated combination therapy is a key factor for therapeutic success in patients HCV infected. To optimize it, goats to reach are to limit dose reduction and premature discontinuation of treatment due to adverse events; to improve the patient compliance to treatment, particularly during the first three months, particularly to ribavirin. Therapeutic education, management of psychiatric adverse events, epoetin alfa, have demonstrated their benefit in terms of sustained virologic response or quality of life. Preparing the treatment with the patient and a multi-disciplinary team, setting successive therapeutic goals with the predictive value of the early virologic response will promote adhesion to treatment. A hepatitis C training program for general practitioners (GP) allows an efficient follow-up of treated patients by a trio hepatologist - GP -nurse and a concrete implication of GP in the field of hepatitis C. Further developments are needed for : taking in account the patient quality of life during treatment to anticipate premature discontinuation, promotion of therapeutic education by specialized nurses, standardization of the diagnosis of depression during treatment, and regular updating of general practitioners on antiviral C treatment (C) 2008 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:S96 / S108
页数:13
相关论文
共 50 条
  • [11] Effectiveness of varied dose of pegylated interferon and ribavirin combination therapy in patients with chronic hepatitis C
    Midha, Vandana
    Sood, Ajit
    Syed, Hissar
    Sood, Neena
    Kumar, Manoj
    Sarin, Shiv K.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A13 - A13
  • [12] Effectiveness of varied dose of pegylated interferon and ribavirin combination therapy in patients with chronic hepatitis C
    Midha, V.
    Sood, A.
    Hissar, S. S.
    Sood, N.
    Kumar, M.
    Sarin, S. K.
    PROCEEDINGS OF THE 16TH CONFERENCE OF THE ASIAN PACIFIC ASSOCIATION FOR THE STUDY OF THE LIVER, 2006, : 1 - +
  • [13] Therapy Induced Anemia in Patients with Chronic Hepatitis C Receiving Combination Therapy of Pegylated Interferon Alpha and Ribavirin
    Mehdi, Syed Ghazanfar
    Faizi, Karim Shah
    Khan, Rao Saad Ali
    PAKISTAN JOURNAL OF MEDICAL & HEALTH SCIENCES, 2013, 7 (01): : 204 - 206
  • [14] Factors associated with adherence to combination therapy of interferon and ribavirin for patients with chronic hepatitis C: Importance of patient selection and treatment experience
    Tanioka, Daisuke
    Iwasaki, Yoshiaki
    Takaguchi, Kouichi
    Ikeda, Hiroshi
    Okamoto, Ryoichi
    Araki, Yasuyuki
    Ando, Masaharu
    Shimoe, Toshinari
    Hashimoto, Noriaki
    Kita, Keiji
    Tomita, Minoru
    Makino, Yasuhiro
    Kobashi, Haruhiko
    Sakaguchi, Kohsaku
    Shiratori, Yasushi
    GASTROENTEROLOGY, 2007, 132 (04) : A200 - A200
  • [15] Combination therapy with daily interferon alpha and ribavirin in naive patients with chronic hepatitis C.
    Rothstein, KD
    Suvannasankha, A
    Digreggorio, K
    Gross, F
    Peikin, S
    Mushnick, A
    Deangelo, C
    Salowe, D
    Siegel, H
    Shaw, E
    Bond, K
    Manzarbeitia, C
    HEPATOLOGY, 1999, 30 (04) : 619A - 619A
  • [16] Combination therapy with interferona and Γincreases host immune response in patients with chronic hepatitis C.
    Kumashiro, R
    Ide, T
    Sasaki, M
    Murashima, S
    Suzuki, H
    Yoshida, H
    Kawahara, T
    Gondo, K
    Maruyama, N
    Sakisaka, S
    Tanikawa, K
    Sata, M
    GASTROENTEROLOGY, 2000, 118 (04) : A1459 - A1459
  • [17] Oxidative stress and IFN plus ribavirin combination therapy in patients with chronic hepatitis C.
    Morisco, F
    Verde, V
    Fogliano, V
    Ritieni, A
    Iasevoli, P
    Tuccillo, C
    De Luise, G
    Caporaso, N
    GASTROENTEROLOGY, 2000, 118 (04) : A1471 - A1471
  • [18] Pegylated Interferon plus Ribavirin Combination Therapy for Chronic Hepatitis C in Patients with Congenital Coagulation Disorders
    Katsarou, O.
    Theodosiades, G.
    Ioannidou, P.
    Nomikou, E.
    Tsevrenis, B.
    Kouraba, A.
    Deutch, M.
    Terpos, E.
    Dourakis, S.
    Karafoulidou, A.
    ACTA HAEMATOLOGICA, 2008, 120 (02) : 63 - 69
  • [19] Cost-effectiveness of combination therapy for relapsers with chronic hepatitis C.
    Buti, M
    Casado, MA
    Fosbrook, L
    Esteban, R
    HEPATOLOGY, 1999, 30 (04) : 197A - 197A
  • [20] Combination of interferon (IFN) induction therapy and ribavirin in chronic hepatitis C.
    Ferenci, P
    Brunner, H
    Vogel, W
    Gschwantler, M
    Datz, C
    Hackl, F
    Steindl-Munda, PE
    Hofer, H
    Mueller, C
    Mueller, C
    GASTROENTEROLOGY, 2000, 118 (04) : A961 - A961